Rafael Rosell spends much of his time researching Lung cancer, Internal medicine, Oncology, Chemotherapy and Cancer research. His research integrates issues of Cancer, Epidermal growth factor receptor, Carcinoma and Surgery in his study of Lung cancer. Rafael Rosell works mostly in the field of Surgery, limiting it down to topics relating to Clinical trial and, in certain cases, Mediastinoscopy.
Rafael Rosell interconnects Survival analysis, KRAS, Proportional hazards model and Phases of clinical research in the investigation of issues within Oncology. His studies deal with areas such as Gene expression, DNA methylation, Immunology, DNA repair and Non small cell as well as Cancer research. His Cisplatin research is multidisciplinary, incorporating elements of Gemcitabine, Urology, Xeroderma pigmentosum and ERCC1.
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy. In most of his Internal medicine studies, his work intersects topics such as Surgery. His work in Oncology addresses subjects such as Adenocarcinoma, which are connected to disciplines such as Lung and KRAS.
His Lung cancer research focuses on subjects like Epidermal growth factor receptor, which are linked to Mutation. Rafael Rosell has researched Cancer research in several fields, including Bioinformatics, Tyrosine kinase and Mutant, Gene, DNA repair. His work carried out in the field of Chemotherapy brings together such families of science as Gastroenterology, Clinical trial and Immunology.
His primary scientific interests are in Lung cancer, Internal medicine, Oncology, Cancer research and Cancer. His work investigates the relationship between Lung cancer and topics such as Epidermal growth factor receptor that intersect with problems in Tyrosine kinase. His work on Chemotherapy, Adenocarcinoma, Lung and KRAS as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
His Oncology study frequently intersects with other fields, such as Hazard ratio. Rafael Rosell combines subjects such as Protein kinase B, Mutant, Receptor tyrosine kinase, Kinase and Osimertinib with his study of Cancer research. His biological study spans a wide range of topics, including Melanoma and Immunology.
Lung cancer, Internal medicine, Oncology, Cancer research and Cancer are his primary areas of study. His research on Lung cancer focuses in particular on Gefitinib. Rafael Rosell works mostly in the field of Internal medicine, limiting it down to topics relating to Surgery and, in certain cases, T790M, as a part of the same area of interest.
His Oncology study integrates concerns from other disciplines, such as Clinical endpoint and Hazard ratio. Rafael Rosell interconnects Tyrosine kinase, non-small cell lung cancer, Targeted therapy, Biomarker and Drug resistance in the investigation of issues within Cancer research. The Cancer study combines topics in areas such as DNA Mutational Analysis, Antibody, Immunology and Tumor cells.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre.
Lancet Oncology (2012)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell;Teresa Moran;Cristina Queralt;Rut Porta.
The New England Journal of Medicine (2009)
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst;Giuseppe Giaccone;Joan H. Schiller;Ronald B. Natale.
Journal of Clinical Oncology (2004)
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone;Roy S. Herbst;Christian Manegold;Giorgio Scagliotti.
Journal of Clinical Oncology (2004)
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial
Jean Yves Douillard;Rafael Rosell;Mario De Lena;Francesco Carpagnano.
Lancet Oncology (2006)
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
Rafael Rosell;Jose Gomez-Codina;Carlos Camps;Jose Maestre.
The New England Journal of Medicine (1994)
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel.
The New England Journal of Medicine (2017)
Detection of Aberrant Promoter Hypermethylation of Tumor Suppressor Genes in Serum DNA from Non-Small Cell Lung Cancer Patients
Manel Esteller;Montserrat Sanchez-Cespedes;Rafael Rosell;David Sidransky.
Cancer Research (1999)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang;Zhenfeng Zhang;Jae Cheol Lee;Luping Lin;Victor Olivas.
Nature Genetics (2012)
Translational Lung Cancer Research
(Impact Factor: 4.726)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: